Loading...
Phase 3 study assessing the efficacy of adding al3818 (catequentinib dihydrochloride, anlotinib hydrochloride) to chemotherapies in subjects with platimum resistant and refractory ovarian carcinoma
Miller, D. Zhou, Q. Banerjee, S. Clamp, Andrew R Qu, P. Huang, M. Nevadunsky, N. Konecny, G.
Miller, D.
Zhou, Q.
Banerjee, S.
Clamp, Andrew R
Qu, P.
Huang, M.
Nevadunsky, N.
Konecny, G.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Miller D, Zhou Q, Banerjee S, Clamp A, Qu P, Huang M, et al. Phase 3 Study Assessing the Efficacy of Adding Al3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to Chemotherapies in Subjects with Platimum Resistant and Refractory Ovarian Carcinoma. International Journal of Gynecological Cancer. 2022 Dec;32:A240-A. PubMed PMID: WOS:000899252300500.